AUTL - חוב לטווח קצר להון Autolus Therapeutics plc

Autolus Therapeutics (AUTL) is a British developer of CAR-T therapies focused on the B2B segment of oncology clinics and expansion within the gene therapy niche. This chart for the stock on the GURU.Markets platform demonstrates a metric at 0.00. The business relies on massive demand from medical centers for leukemia therapy, while a unique patent for T-cell modification will provide the company with global reach and high profitability following certification.

Autolus Therapeutics (AUTL) is developing innovative cancer gene therapies, the demand for which remains independent of macroeconomic cycles. Mathematically, this metric compares total liabilities with a maturity of over one year against the amount of equity. This ratio determines the extent to which the business's financial stability depends on leverage relative to shareholder value. By analyzing the current level of short-term capital burden, an investor can assess the risks of overpaying for the asset.